Mixed response to osimertinib and the beneficial effects of additional local therapy

BACKGROUND: Although non‐small cell lung cancers (NSCLCs) harboring EGFR mutations initially respond well to EGFR‐tyrosine kinase inhibitors (TKIs), they typically progress after approximately one year. The EGFR T790M mutation is the most common resistance mechanism. NSCLCs with T790M respond well t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Shinno, Yuki, Goto, Yasushi, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449255/
https://ncbi.nlm.nih.gov/pubmed/30735003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12991
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars